5HT3 receptor antagonists, also called serotonin blockers, is group of drugs used for the prevention and treatment of nausea and vomiting caused after chemotherapy, radiation therapy, and post-operative surgical procedures. 5HT3 is an abbreviation of 5-hydroxytryptamine, also called serotonin. Serotonin is a chemical substance produced by nerve cells that sends signal between these cells and are most commonly found in the digestive tract. After chemotherapy or radiation therapy and post-operative surgical procedures, the inner linings of gastrointestinal tracts release serotonin chemical, which acts as neurotransmitter and stimulates the nerves involved in the vomit reflux. These drugs prevent serotonin from binding to 5HT3 receptors in the small intestine, and prevent the likelihood of nausea and vomiting after chemo or radiation therapy. 5HT3 drugs are also used to prevent nausea and vomiting caused due anesthesia given before surgery. Five different types of serotonin blockers are available: dolasetron, granisetron, ondansetron, tropisetron, and palonosetron. These drugs are being widely used in hospitals and ambulatory surgery centers where chemotherapy and radiation therapy procedures are frequently performed.

The global 5HT3 receptor antagonists market is projected to be driven by high prevalence and rise in incidence of different types of cancer. According to Cancer Research UK, over 14.1 million new cases of cancer occurred worldwide in 2012. Moreover, 70% to 80 % of cancer patients are affected by chemotherapy-induced nausea and vomiting (CINV) and 50% to 80% patients are affected by radiation-induced nausea and vomiting (RNIV). Increase in number of patients undergoing chemotherapy and radiation therapy owing to well-established health care facilities, high health care expenditure per capita, and favorable medical reimbursement policies in developed nations has contributed to the growth of the global 5HT3 receptor antagonists market. Moreover, increase in applications of these drugs in post-operative surgical procedures for the prevention and treatment of nausea and vomiting is likely to boost demand during the forecast period. Furthermore, new drug approval for the treatment of acute to severe CINV, RINV, and post-operative induced nausea and vomiting presents significant opportunities for global players operating in this market. Increased R&D investments by pharmaceutical and biotechnology companies for the development of highly effective and efficient drugs with minimum side effects is projected to fuel demand for 5HT3 receptor antagonists during the forecast period.

 The global 5HT3 receptor antagonists market can be segmented based on product type, application, and region. In terms of product type, the market can be categorized into first generation and second generation. Dolasetron, granisetron, and ondansetron are included in the first generation receptor antagonists. Palonosetron is a second-generation serotonin blocker. The second generation receptor antagonists segment is projected to account for leading share of the global 5HT3 receptor antagonists market. Based on application, the global 5HT3 receptors antagonists market can be segmented into CINV, RINV, and post-operative nausea and vomiting (PONV). The CINV segment is expected to dominate the global market, with exponential growth rate during the forecast period.

Geographically, the global 5HT3 receptors antagonists market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to dominate the global market owing to high prevalence and incidence of cancer. In 2016, an estimated 1,685,210 new cases of cancer were diagnosed and 595,650 people are likely to succumb to cancer in the U.S. Rise in incidence of cancer in Asia Pacific, increase in access to health care facilities for chemotherapy and radiation therapy, and surge in disposable income make Asia Pacific the fastest growing market for 5HT3 receptors antagonists during the forecast period.

Key players operating in the global 5HT3 receptors antagonists market include GlaxoSmithKline plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai, Inc., Novartis Pharmaceuticals Corporation, Helsinn Holding S.A., Sanofi, Midatech Pharma US, Inc., Kyowa Kirin, Inc., and Tesaro, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


5ht3 Receptor Antagonists Market

Pre Book